Progress in understanding humoral rejection in kidney transplantation: implications for patient management
Détails
ID Serval
serval:BIB_10BFC79C818E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Editorial
Collection
Publications
Institution
Titre
Progress in understanding humoral rejection in kidney transplantation: implications for patient management
Périodique
Nefrologia
ISSN
0211-6995
Statut éditorial
Publié
Date de publication
08/2001
Peer-reviewed
Oui
Volume
21
Numéro
4
Pages
327-31
Notes
Editorial
Research Support, Non-U.S. Gov't --- Old month value: Jul-Aug
Research Support, Non-U.S. Gov't --- Old month value: Jul-Aug
Résumé
After more than 40 years of clinical renal transplantation, the contribution of humoral immunity to the pathogenesis of allograft rejection is progressively being clarified. With the advent of a new generation of immunosuppressive agents, the production and consequences of anti-donor alloantibodies can now be controlled. In the upcoming years, immunosuppressive regimens that will specifically control both T- and B-cell responses may further improve long-term allograft survival, if the immunosuppressive efficacy of such regimens is not hampered by an increase in infectious, neoplastic or cardio-vascular complications.
Mots-clé
ABO Blood-Group System/immunology
Acute Disease
Antibody Formation
Antibody-Dependent Cell Cytotoxicity
Chronic Disease
Complement C4/immunology
*Complement C4b
Graft Rejection/drug therapy/*immunology/prevention & control
HLA Antigens/*immunology
Histocompatibility Testing
Humans
Immunoglobulins, Intravenous/therapeutic use
Immunosuppression/methods
Immunosuppressive Agents/therapeutic use
Isoantibodies/biosynthesis/*immunology
Kidney Transplantation/*immunology
Mycophenolic Acid/therapeutic use
Peptide Fragments/immunology
Plasmapheresis
Tacrolimus/therapeutic use
Pubmed
Web of science
Création de la notice
29/01/2008 14:52
Dernière modification de la notice
20/08/2019 13:37